Products with Anti-inflammatory bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1239 | Acetylcorynoline |
| Acetylcorynoline has anti-inflammatory properties, it also has potential to improve parkinson's disease, it may exert its effects by decreasing egl-1 expression to suppress apoptosis pathways and by increasing rpn5 expression to enhance the activity of proteasomes. Acetylcorynoline may be one of the potent immunosuppressive agents through the blockage of dendritic cells maturation and function. It has protective action against experimental liver injury in mice. | |
| BCN1240 | Dehydrodiisoeugenol |
| Dehydrodiisoeugenol has anti-inflammatory activity, it inhibited the expression of the COX-2, proteolysis of inhibitor κB-α and transcriptional activity of NF-κB. Dehydrodiisoeugenol can cross the blood-brain barrier rapidly, it may be developed into an effective anxiogenic agent. | |
| BCN1242 | Myrislignan |
| Myrislignan has anti-inflammatory, and anti-cancer activities, it inhibited NF-κB signalling pathway activation, inhibited the proliferation of A549 cells in a dose- and time-dependent manner, it also significantly induced apoptosis and cell cycle arrest in A549 cells. | |
| BCN1246 | Ginsenoside Compound K |
| Ginsenoside compound K (C-K) is a metabolite of the protopanaxadiol-type saponins of Panax ginseng C.A. Meyer, has long been used to treat against the development of cancer, inflammation, allergies, and diabetes; C-K acts as a unique HUVEC migration inhibitor by regulating MMP expression, as well as the activity of SPHK1 and its related sphingolipid metabolites. C-K exhibits anti-inflammatory effects by reducing iNOS and COX-2, C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively. C-K promotes Aβ clearance by enhancing autophagy via the mTOR signaling pathway in primary astrocytes. | |
| BCN1252 | Isolinderalactone |
| Isolinderalactone shows anti-inflammatory and anticancer capacity, it induces apoptosis in MDA-MB-231 cells and suppresses STAT3 signaling pathway through regulation of SOCS3 and miR-30c, may become a novel treatment for triple-negative breast cancer in the future; it exhibits moderate iNOS inhibitory activity, with the IC50 value of 0.30 uM. | |
